15. - 16.06.2015 - Sanofi-Genzyme Cellular Assay Forum

Sanofi Cellular Assay Forum Resized

 Develop a New Generation of Assays

Over years it was a common thought that it was adequate to construct target-specific cellular assays to find hits and drive lead optimization. These assays were often relatively inexpensive and robust. They were not, however, always physiologically relevant or predictive of activity in patients.
How do we make assays that are predictive of human disease yet robust enough to provide reliable data for lead optimization?
The Sanofi-Genzyme Cellular Assay Forum will explore ways to develop this new generation of assays. 

15 - 16 June, 2015

The Conference Centre at Waltham Woods - Waltham, WA, USA

Meet InSphero at Table #102

State of the art 3D cardiac and neural microtissue models for toxicity testing and disease modeling

Dr. Jan Lichtenberg
CEO and co-founder InSphero AG

In vivo animal models are primarily employed to assess cardio-and neurotoxic effects of chemicals and potential candidate compounds in drug development, while in vitro testing is limited to HTS compatible, low complexity 2D cultures of primary cells or cell lines, or testing on more sophisticated low throughput explant cultures. 3D cardiac and neuronal microtissues not only represent more biologically relevant model systems in which to investigate drug-related toxicity, but also hold promise for the development and assessment of more organotypic in vitro disease models using genetically modified cells and/or compounds to induce a diseased phenotype. This talk will cover InSphero's 3D InSight™ Cardiac and Neuronal Microtissues, with emphasis on their structural and functional characterization, and downstream endpoint compatibility afforded by the scaffold-free 3D culture platform employed in their production.

More information 

Company video